high-grade serous ovarian cancers . transformation to promote formation of fallopian tube derived Cyclin E 1 deregulation occurs early in secretory cell

[1]  I. Shih,et al.  Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. , 2014, Annual review of pathology.

[2]  R. Drapkin,et al.  Coming into focus: the nonovarian origins of ovarian cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  T. Helleday,et al.  Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress , 2013, Oncogene.

[4]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[5]  I. Shih,et al.  Rsf‐1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development , 2013, The Journal of pathology.

[6]  R. Drapkin,et al.  Primary culture and immortalization of human fallopian tube secretory epithelial cells , 2012, Nature Protocols.

[7]  Hong Wu,et al.  A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. , 2012, Cancer cell.

[8]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[9]  G. Mills,et al.  LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients , 2012, PLoS genetics.

[10]  Joe W. Gray,et al.  Genome Wide DNA Copy Number Analysis of Serous Type Ovarian Carcinomas Identifies Genetic Markers Predictive of Clinical Outcome , 2012, PloS one.

[11]  M. Rosner,et al.  An integrated view of cyclin E function and regulation , 2012, Cell cycle.

[12]  B. Kerem,et al.  Nucleotide Deficiency Promotes Genomic Instability in Early Stages of Cancer Development , 2011, Cell.

[13]  R. Drapkin,et al.  Modeling high-grade serous ovarian carcinogenesis from the fallopian tube , 2011, Proceedings of the National Academy of Sciences.

[14]  D. Ginsberg,et al.  miR-15 and miR-16 Are Direct Transcriptional Targets of E2F1 that Limit E2F-Induced Proliferation by Targeting Cyclin E , 2011, Molecular Cancer Research.

[15]  Kylie L. Gorringe,et al.  Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer , 2010, PloS one.

[16]  David D. L. Bowtell,et al.  The genesis and evolution of high-grade serous ovarian cancer , 2010, Nature Reviews Cancer.

[17]  Kylie L. Gorringe,et al.  Copy Number Analysis Identifies Novel Interactions Between Genomic Loci in Ovarian Cancer , 2010, PloS one.

[18]  G. Ning,et al.  A Pathologist's Road Map to Benign, Precancerous, and Malignant Intraepithelial Proliferations in the Fallopian Tube , 2010, Advances in anatomic pathology.

[19]  A. Składanowski,et al.  H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy , 2010, Journal of nucleic acids.

[20]  K. Hunt,et al.  Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. , 2010, Cancer research.

[21]  Kentaro Nakayama,et al.  Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer , 2010, Cancer.

[22]  I. Shih,et al.  Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase , 2010, Modern Pathology.

[23]  M. Hirsch,et al.  Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. , 2009, Gynecologic oncology.

[24]  Varda Rotter,et al.  When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.

[25]  R. Drapkin,et al.  Ovarian Cancer Pathogenesis: A Model in Evolution , 2009, Journal of oncology.

[26]  Joshy George,et al.  Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas , 2009, Clinical Cancer Research.

[27]  Jesse D. Martinez,et al.  Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. , 2008, Neoplasia.

[28]  R. Drapkin,et al.  Serous Carcinogenesis in the Fallopian Tube: A Descriptive Classification , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[29]  B. Clurman,et al.  p53 and SCFFbw7 cooperatively restrain cyclin E-associated genome instability , 2007, Oncogene.

[30]  D. Albertson,et al.  DNA profiling of primary serous ovarian and Fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation‐dependent probe amplification , 2007, The Journal of pathology.

[31]  E. Dmitrovsky,et al.  Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas , 2007, Proceedings of the National Academy of Sciences.

[32]  R. Berkowitz,et al.  Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.

[33]  J. Garber,et al.  A candidate precursor to serous carcinoma that originates in the distal fallopian tube , 2007 .

[34]  S. Reed,et al.  Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland , 2006, Oncogene.

[35]  Dimitris Kletsas,et al.  Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints , 2006, Nature.

[36]  Christopher P Crum,et al.  The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.

[37]  James M. Roberts,et al.  A mouse model for cyclin E-dependent genetic instability and tumorigenesis. , 2005, Cancer cell.

[38]  Ajay N. Jain,et al.  Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in Fallopian tube carcinoma , 2003, Oncogene.

[39]  B. Clurman,et al.  p53 and p21 Form an Inducible Barrier that Protects Cells against Cyclin E-cdk2 Deregulation , 2002, Current Biology.

[40]  P. V. van Diest,et al.  Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer , 2001, The Journal of pathology.

[41]  Rochelle L. Garcia,et al.  Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. , 2001, Gynecologic oncology.

[42]  S. Reed,et al.  Deregulated cyclin E induces chromosome instability , 1999, Nature.

[43]  L. Johnson,et al.  Effects of Phosphorylation of Threonine 160 on Cyclin-dependent Kinase 2 Structure and Activity* , 1999, The Journal of Biological Chemistry.

[44]  W. Hahn,et al.  Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Bortner,et al.  Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E , 1997, Molecular and cellular biology.

[46]  P. Olive,et al.  The comet assay: a method to measure DNA damage in individual cells , 2006, Nature Protocols.

[47]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.